{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:18:51Z","timestamp":1771237131705,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40256-020-00426-w","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T01:02:42Z","timestamp":1599872562000},"page":"181-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Hong-yu","family":"Kuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-an","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-hui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"issue":"1","key":"426_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1183\/09031936.00092306","volume":"30","author":"AJ Peacock","year":"2007","unstructured":"Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104\u20139.","journal-title":"Eur Respir J"},{"issue":"12","key":"426_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cpcardiol.2011.08.002","volume":"36","author":"VV Mclaughlin","year":"2011","unstructured":"Mclaughlin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr Prob Cardiol. 2011;36(12):461\u2013517.","journal-title":"Curr Prob Cardiol"},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67\u2013119.","journal-title":"Eur Heart J"},{"issue":"2","key":"426_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1378\/chest.11-1460","volume":"142","author":"RL Benza","year":"2012","unstructured":"Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448\u201356.","journal-title":"Chest"},{"issue":"5","key":"426_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1755-5922.2010.00158.x","volume":"28","author":"SG Raja","year":"2010","unstructured":"Raja SG. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther. 2010;28(5):65\u201370.","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"426_CR6","first-page":"30","volume":"11","author":"K Chin","year":"2002","unstructured":"Chin K, Channick R. Bosentan therapy for pulmonary arterial hypertension. Acc Curr J Rev. 2002;11(5):30\u20134.","journal-title":"Acc Curr J Rev"},{"issue":"6","key":"426_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/14750708.2.6.843","volume":"2","author":"SA Antoniu","year":"2005","unstructured":"Antoniu SA. Bosentan for treatment of pulmonary arterial hypertension. Therapy. 2005;2(6):843\u20137.","journal-title":"Therapy"},{"issue":"6","key":"426_CR8","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/crj.12774","volume":"12","author":"X Chen","year":"2018","unstructured":"Chen X, Zhai Z, Huang K, et al. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-analysis. Clin Respir J. 2018;12(6):2065\u201374.","journal-title":"Clin Respir J"},{"key":"426_CR9","doi-asserted-by":"crossref","unstructured":"You R, Qian X, Tang W, et al. Cost effectiveness of bosentan for pulmonary arterial hypertension: a systematic review. Can Respir J. 2018;1015239.","DOI":"10.1155\/2018\/1015239"},{"issue":"10","key":"426_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.healun.2004.12.113","volume":"24","author":"RE Girgis","year":"2005","unstructured":"Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005;24(10):1628\u201331.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"426_CR11","first-page":"1","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Epidemiol Biostat Public Health. 2009;6(4):1\u201334.","journal-title":"Epidemiol Biostat Public Health"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley-Blackwell; 2008. p. S38."},{"issue":"1","key":"426_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2\u201310.","journal-title":"J Evid Based Med"},{"issue":"4","key":"426_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ahj.2005.07.005","volume":"150","author":"I Schulze-Neick","year":"2005","unstructured":"Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J. 2005;150(4):716.","journal-title":"Am Heart J"},{"issue":"8","key":"426_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/hrt.2006.089185","volume":"93","author":"GP Diller","year":"2007","unstructured":"Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007;93(8):974\u20136.","journal-title":"Heart"},{"issue":"3","key":"426_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/hrt.2006.100388","volume":"93","author":"SC Apostolopoulou","year":"2007","unstructured":"Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart. 2007;93(3):350\u20134.","journal-title":"Heart"},{"issue":"3","key":"426_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2362.2006.01685.x","volume":"36","author":"O Sitbon","year":"2006","unstructured":"Sitbon O, Beghetti M, Petit J, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest. 2006;36(3):25\u201331.","journal-title":"Eur J Clin Invest."},{"issue":"5","key":"426_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cardfail.2012.02.004","volume":"18","author":"MG Kaya","year":"2012","unstructured":"Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18(5):379\u201384.","journal-title":"J Card Fail"},{"issue":"3","key":"426_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijcard.2011.07.009","volume":"164","author":"M D'Alto","year":"2013","unstructured":"D'Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol. 2013;164(3):323\u20136.","journal-title":"Int J Cardiol"},{"issue":"1","key":"426_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2011.06.064","volume":"164","author":"JC Vis","year":"2013","unstructured":"Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164(1):64\u20139.","journal-title":"Int J Cardiol"},{"issue":"2","key":"426_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.repc.2012.02.023","volume":"32","author":"R Baptista","year":"2013","unstructured":"Baptista R, Castro G, da Silva AM, et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013;32(2):123\u20139.","journal-title":"Rev Port Cardiol"},{"issue":"3","key":"426_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2362.2006.01684.x","volume":"36","author":"F Cozzi","year":"2006","unstructured":"Cozzi F, Montisci R, Marotta H, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest. 2006;36(3):49\u201353.","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"426_CR23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/ard.2007.079921","volume":"67","author":"CP Denton","year":"2008","unstructured":"Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67(9):1222\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"426_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1183\/09031936.00094808","volume":"33","author":"B Degano","year":"2009","unstructured":"Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009;33(1):92\u20138.","journal-title":"Eur Respir J"},{"issue":"5","key":"426_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","volume":"27","author":"S Provencher","year":"2006","unstructured":"Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589\u201395.","journal-title":"Eur Heart J"},{"issue":"2","key":"426_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1183\/09031936.05.00054804","volume":"25","author":"VV McLaughlin","year":"2005","unstructured":"McLaughlin VV. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244\u20139.","journal-title":"Eur Respir J"},{"key":"426_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijcard.2015.08.080","volume":"202","author":"RMF Berger","year":"2016","unstructured":"Berger RMF, Haworth SG, Bonnet D, et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric formulation of bosentan in pulmonary arterial hypertension. Int J Cardiol. 2016;202:52\u20138.","journal-title":"Int J Cardiol"},{"issue":"7","key":"426_CR28","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.rmed.2006.12.007","volume":"101","author":"HH Hsu","year":"2007","unstructured":"Hsu HH, Chen JS, Chen RJ, et al. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Respir Med. 2007;101(7):1556\u2013622.","journal-title":"Respir Med"},{"issue":"3","key":"426_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/CRD.0b013e3181d4e921","volume":"18","author":"JR Anderson","year":"2010","unstructured":"Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010;18(3):148\u201362.","journal-title":"Cardiol Rev"},{"key":"426_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001;358:1119\u201323.","journal-title":"Lancet"},{"key":"426_CR31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896\u2013903.","journal-title":"N Engl J Med"},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","volume":"24","author":"M Humbert","year":"2004","unstructured":"Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353\u20139.","journal-title":"Eur Respir J"},{"key":"426_CR33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Galie","year":"2008","unstructured":"Galie N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet. 2008;371:2093\u2013100.","journal-title":"Lancet"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","volume":"114","author":"N Galie","year":"2006","unstructured":"Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmernger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48\u2013544.","journal-title":"Circulation"},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2016.12.092","volume":"234","author":"MM Duo-Ji","year":"2017","unstructured":"Duo-Ji MM, Long ZW. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: a network meta-analysis. Int J Cardiol. 2017;234:90\u20138.","journal-title":"Int J Cardiol"},{"issue":"6","key":"426_CR36","first-page":"887","volume":"3","author":"E Gabbay","year":"2007","unstructured":"Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2007;3(6):887\u2013900.","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"426_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2362.2006.01688.x","volume":"36","author":"VV Mclaughlin","year":"2006","unstructured":"Mclaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;36(3):10\u20135.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"426_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","volume":"30","author":"V Thakkar","year":"2016","unstructured":"Thakkar V, Lau EMT. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol. 2016;30(1):22\u201338.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"426_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/s-0029-1233312","volume":"30","author":"PM Hassoun","year":"2009","unstructured":"Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med. 2009;30(4):429\u201339.","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"426_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2165\/00003495-200868080-00004","volume":"68","author":"N Galie","year":"2008","unstructured":"Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger\u2019s Syndrome. Drugs. 2008;68(8):1049\u201366.","journal-title":"Drugs"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00426-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:41:39Z","timestamp":1631407299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00426-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00426-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"12 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hong-yu Kuang, Qiang Li, Hua-an Du, Min Chen, and Yue-hui Yin declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived because each study has been previously published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All co-authors have consented the participation in this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All co-authors have consented for publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":":The relevant data and materials can be requested from the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The codes for meta-analyses with the statistical software Stata 14.1 can be requested from the authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}